Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib vs Placebo in Adjuvant ALK+ NSCLC
NCT05341583Phase 3Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- May 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started May 2022; status: recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05341583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341583.